Scholarlink

Purpose <p>The aim of our review is to report the thyroid orbitopathy treatments, focusing on novel medicines and ongoing research.</p> Design <p>Review developed by a research group at Catholic University of the Sacred Heart.</p> Methods <p>Overview of the literature synthesizing the findings of literature retrieved from searches of computerized databases, hand searches and authoritative texts.</p> Summary <p>Although minimally invasive surgical techniques have been developed, current research is placing greater emphasis on the use of biological and immunosuppressive drugs for the treatment of thyroid eye disease (TED). Teprotumumab, a monoclonal antibody targeting the insulin-like growth factor-1 receptor, has just been approved by the Food and Drug Administration as a therapy for the treatment of TED. This approval is based on its ability to relieve both the clinical signs and symptoms of the condition, such as proptosis and diplopia. Synthetic peptides imitating T cell epitopes and TSHR-CAR-T cells represent a potential and novel immunotherapeutic strategy.</p> Conclusions <p>The growth of several novel therapies highlights the intricate nature of the disease's aetiology and the multitude of processes involved in its regulation. These advancements reveal a future direction focused on personalized treatment of Graves' orbitopathy. The integration of multiple disciplines is becoming increasingly indispensable in the management of patients with this disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Thyroid-related orbitopathy: clinical overview, novel medical treatments and the role of orbital surgery

  • 期刊论文

  • 发表日期：

    2025年5月3日

查看全文
  • Federico Giannuzzi,
  • Matteo Mario Carlà,
  • Emanuele Crincoli,
  • Gloria Gambini,
  • Lorenzo Hu,
  • Francesco Boselli,
  • Giovanni Cuffaro,
  • Claudio Parrilla,
  • Mario Rigante,
  • Monica Maria Pagliara,
  • Stanislao Rizzo,
  • Gustavo Savino

摘要

Purpose

The aim of our review is to report the thyroid orbitopathy treatments, focusing on novel medicines and ongoing research.

Design

Review developed by a research group at Catholic University of the Sacred Heart.

Methods

Overview of the literature synthesizing the findings of literature retrieved from searches of computerized databases, hand searches and authoritative texts.

Summary

Although minimally invasive surgical techniques have been developed, current research is placing greater emphasis on the use of biological and immunosuppressive drugs for the treatment of thyroid eye disease (TED). Teprotumumab, a monoclonal antibody targeting the insulin-like growth factor-1 receptor, has just been approved by the Food and Drug Administration as a therapy for the treatment of TED. This approval is based on its ability to relieve both the clinical signs and symptoms of the condition, such as proptosis and diplopia. Synthetic peptides imitating T cell epitopes and TSHR-CAR-T cells represent a potential and novel immunotherapeutic strategy.

Conclusions

The growth of several novel therapies highlights the intricate nature of the disease's aetiology and the multitude of processes involved in its regulation. These advancements reveal a future direction focused on personalized treatment of Graves' orbitopathy. The integration of multiple disciplines is becoming increasingly indispensable in the management of patients with this disease.